Login to Your Account



Clinic Roundup


Tuesday, April 24, 2012
• Asubio Pharmaceuticals Inc., of Paramus, N.J., started a Phase II trial of SUN13837, a therapy designed to improve neurological function in patients with newly diagnosed acute spinal cord injury. The company is working with 60 acute trauma centers throughout the U.S. and Canada to enroll 164 patients in the randomized, placebo-controlled trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription